BridgeBio Pharma Inc

BBIO

Equity

ISIN null / Valor 48204826

NASDAQ (2025-11-21)

USD 68.11+5.40%

BridgeBio Pharma Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

BridgeBio Pharma Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for genetic diseases. In 2022, Sentynl Therapeutics, Inc. acquired global rights to NULIBRY and is responsible for the ongoing development and commercialization of NULIBRY in the U.S. and developing, manufacturing, and commercializing fosdenopterin globally. The company's mission is to address unmet medical needs in rare diseases by advancing a diverse pipeline of potential treatments.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Breakdown

The company generated $110.6 million in total revenue, with $71.5 million coming from U.S. Attruby net product revenue, $1.6 million from royalty revenue, and $37.5 million from license and services revenue.

Commercial Momentum

Attruby’s launch continues to accelerate, with 3,751 unique patient prescriptions written by 1,074 providers since its FDA approval in November 2024. This momentum underlines the growing adoption across both centers of excellence and community practices.

Robust Cash Position

BridgeBio ended Q2 2025 with $756.9 million in cash, cash equivalents, and marketable securities, ensuring the company is well-capitalized to drive the Attruby launch further and support key Phase 3 trials.

Pipeline and Future Milestones

The report also highlights a strong pipeline, including pivotal Phase 3 trials with expected topline results in fall 2025 for BBP-418 and encaleret, as well as early 2026 for infigratinib, setting the stage for future rare disease launches.

Summarized from source with an LLMView Source

Key figures

193%1Y

675%3Y

54.0%5Y

Performance

51.4%1Y

72.6%3Y

94.3%5Y

Volatility